Table 1 Patient characteristics.
From: Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)
HIV | HIV/HCV | p-value | |
|---|---|---|---|
Total number of patients (%) | 176 (54.7) | 146 (45.3) | — |
Demographic data Age [median years, range] | 43 (20–76) | 41 (24–65) | 0.007 |
Gender: male/female [% male] | 153/23 | 129/17 | 0.699 |
Risk category n [%] | |||
Haemophilia Intravenous drug use Homosexual Heterosexual Unknown routes of transmission | 4 (2.3) 3 (1.7) 98 (55.7) 27 (15.3) 44 (25.0) | 88 (60.3) 37 (25.3) 9 (6.2) 5 (3.4) 7 (4.8) | <0.001 0.001 <0.001 0.001 0.001 |
CD4 T-cell counts at study entry [cells/μl] | 423 (8–1303) | 372 (6–1941) | <0.001 |
CD4 T-cell counts at end of study [cells/μl] | 530 (35–1800) | 361 (5–1765) | <0.001 |
Platelets [G/L] | 205 (64–395) | 174 (30–435) | 0.001 |
AST/GOT [U/L] | 26 (4–168) | 38 (7–536) | 0.004 |
ALT/GPT [U/L] | 29 (11–122) | 55 (12–449) | 0.002 |
GGT [U/L] | 39 (3–669) | 64 (7–957) | 0.007 |
Bilirubin [mg/dl] | 0.49 (0.18–3.36) | 0.64 (0.15–7.23) | 0.029 |
Hepatitis B serology HBs Ag positive n (%) | 17 (9.7) | 30 (20.6) | 0.018 |
HCV treatment (%) SVR (%) | — | 56 (38.4) 30 (20.6) | n.a. |
HIV loads at study entry [median copies/ml, range] at last observation | 0 (0.0–456248) 0 (0.0–456248) | 0 (0.0–283990) 0 (0.0–587508) | 0.805 0.179 |
Patients with detectable HIV VL n [%] | |||
At study entry At end of observation/death | 75 (42.6) 26 (14.8) | 71 (48.6) 22 (15.1) | 0.293 0.883 |
HAART regimes n [%] | |||
NRTI NNRTI PI Other antiretrovirals | 17 (9.7) 27 (15.3) 117 (66.5) 3 (1.7) | 16 (10.9) 19 (13.0) 92 (63.0) 4 (2.7) | 0.869 0.653 0.615 0.465 |
